Physician profile
Hernan S Schmidt
NPI 1821139494
$7,797.85
in general payments reported to CMS, 2019-2025
25 companies · $2,396 in 2025
The $2,396 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $338 · 2021: $585 · 2022: $606 · 2023: $1,319 · 2024: $1,946 · 2025: $2,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,634 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,634.06 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,457.94 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,164.77 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $961.77 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $846.49 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $813.29 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $547.18 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $436.78 | 2024-2025 | Cobenfy |
| Eisai INC. | $287.43 | 2021-2025 | |
| Allergan, INC. | $201.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.51 | 2019-2025 | Trintellix |
| Alkermes, INC. | $176.83 | 2020-2023 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $159.51 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $134.37 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.13 | 2020-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $79.67 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $38.91 | 2024 | |
| Sage Therapeutics, LLC | $35.02 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.11 | 2024 | Rexulti |
| Lilly USA, LLC | $19.58 | 2024 | Amyvid |
| Shire North American Group INC | $16.00 | 2019 | |
| Merck Sharp & Dohme LLC | $15.82 | 2023 | Belsomra |
| Lundbeck LLC | $15.34 | 2019 | |
| Noven Therapeutics, LLC | $14.23 | 2024 | Secuado |
| Supernus Pharmaceuticals, INC. | $14.17 | 2025 | Qelbree |
| Owp Pharmaceuticals, INC. | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.